中科微点-全球专利检索

  1. Login
  2. Sign Up
Invention Grant
US07807457B2 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars 失效
含有人类尿激酶纤溶酶原激活物基因的重组病毒载体和非病毒载体及其在治疗各种肝，肾，肺，胰腺和心脏纤维化和肥厚性瘢痕中的应用

  • Patent Title: Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars
  • Patent Title (中): 含有人类尿激酶纤溶酶原激活物基因的重组病毒载体和非病毒载体及其在治疗各种肝，肾，肺，胰腺和心脏纤维化和肥厚性瘢痕中的应用
  • Application No.: US10432989
    Application Date: 2000-11-30
  • Publication No.: US07807457B2
    Publication Date: 2010-10-05
  • Inventor: Juan Armendariz Borunda , Estuardo Aguilar Cordova
  • Applicant: Juan Armendariz Borunda , Estuardo Aguilar Cordova
  • Applicant Address: MX Col. Prado Coapa
  • Assignee: TGT Laboratories, S.A. De C.V.
  • Current Assignee: TGT Laboratories, S.A. De C.V.
  • Current Assignee Address: MX Col. Prado Coapa
  • Agency: Morgan, Lewis & Bockius LLP
  • Priority: MX011713 20001228
  • International Application: PCT/MX00/00050 WO 20001130
  • International Announcement: WO02/44393 WO 20020606
  • Main IPC: C12N5/00
  • IPC: C12N5/00 ;  C12N15/00
Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars
Abstract:
The present invention encompasses a modified human urokinase plasminogen activator (“huPA”) gene, which was inserted in the adenoviral vector (pAd-.DELTA.huPA), which is not secreted and does not provoke hypercoagulation or spontaneous internal bleeding. It has been discovered that huPa induced a dramatic fibrosis reduction (85%) on day 10 of vector administration, compared to control cirrhotic rats and 55% hepatocyte proliferation increase. Liver function tests (ALT, AST, alkaline phosphatase and bilirubin) dropped to nearly normal levels and hepatocyte proliferation was observed. The invention also encompasses gene therapy with modified huPA to treat disorders in patients. In a particular embodiment, the invention encompasses a treatment for patients with liver cirrhosis.
Abstract(Chinese):

本发明包括插入到腺病毒载体（pAd.DELTA.huPA）中的修饰的人类尿激酶纤溶酶原激活物（“huPA”）基因，其不分泌并且不引起高凝血或自发性内部出血。 与对照肝硬化大鼠相比，huPa在载药给药第10天引起剧烈的纤维化减少（85％），55％的肝细胞增殖增加。 肝功能检查（ALT，AST，碱性磷酸酶和胆红素）降至几乎正常水平，观察肝细胞增殖。 本发明还包括用修饰的huPA治疗患者的疾病的基因疗法。 在一个具体实施方案中，本发明包括用于肝硬化患者的治疗。

Public/Granted literature
Information query
Espacenet
Patent Agency Ranking
0/0